Business Context and Reporting Period
This Form 8-K is filed by India Globalization Capital, Inc. (not IGC Pharma, Inc.) for the reporting period ending March 16, 2016. The filing discloses a material event regarding the unregistered sale of equity securities.
Key Financial Metrics
- Capital Raised: $600,000 total purchase price.
- Shares Issued: 1,428,571 shares of common stock.
- Post-Transaction Outstanding Shares: Approximately 22,536,934 shares.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The primary material change is the completion of a private placement on March 16, 2016. The company issued restricted common shares to unaffiliated investors under a "Q4 2016 Stock Purchase Agreement." This transaction increased the total share count to approximately 22.5 million shares.
Guidance, Outlook, and Risks
- Transaction Status: The offering closed on March 16, 2016, subject to customary closing conditions.
- Regulatory Basis: The transaction was not registered under the Securities Act of 1933, relying on the exemption provided by Section 4(a)(2).
- Risks: The filing contains forward-looking statements regarding the anticipated closing and future operations. Management directs investors to risks detailed in the company's Form 10-K and Form 10-Q filings.
- Unusual Items: None reported beyond the standard private placement disclosure.
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("IGC Pharma, Inc.") and the filing registrant ("India Globalization Capital, Inc.").
- Confirm the final share count of 22,536,934 in subsequent filings to ensure no further dilution occurred.
- Review the attached "Q4 2016 Stock Purchase Agreement" (Exhibit 10.1) for specific investor rights or restrictions.
- Examine the company's most recent Form 10-K or 10-Q for liquidity status, as this 8-K does not disclose cash balances or debt levels.